Central prostaglandin synthesis pathways

The central prostaglandin synthesis pathways refer to the biochemical processes within the central nervous system (CNS) responsible for the production of prostanoids, particularly prostaglandin E2 (PGE2) [1, 10]. These pathways are primarily mediated by the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which convert arachidonic acid into prostaglandin H2, followed by the action of specific synthases [6, 11]. Prostaglandins produced in the CNS are critical mediators of pain signaling (nociception) and the regulation of the hypothalamic thermoregulatory set-point [1, 3]. This pathway is the primary target of acetaminophen (paracetamol), which exerts its analgesic and antipyretic effects by inhibiting central COX activity, likely due to the low-peroxide environment of the brain [2, 4, 5]. Unlike peripheral prostaglandin inhibition, targeting the central pathway typically does not produce significant anti-inflammatory effects in the periphery [1, 4]. Other drugs, such as metamizole, also interact with these pathways to provide pain relief and fever reduction [8]. Therapeutic challenges include the risk of severe hepatotoxicity associated with the accumulation of toxic metabolites from drugs like acetaminophen, as well as the potential for masking symptoms of underlying infections [1, 3, 4]. Research into these pathways continues to explore the role of specific COX variants and the interaction with the endocannabinoid system [2, 4].

Other names

CNS prostaglandin synthesisCentral cyclooxygenase pathwayCentral PG synthesis

Inhibition of central cyclooxygenase (COX) enzymes, primarily by acting as a reducing agent at the peroxidase site, thereby preventing the formation of pro-inflammatory and pyretic prostaglandins like PGE2 in the brain and spinal cord [1, 2, 4].